Under the agreement, the hospital will absorb IDI’s operating losses for the next five years for up to $1 million in any given fiscal year. In the fiscal year ended Sept. 30, 2011, IDI had $29.9 million in revenue and a net operating loss of $9.1 million, according to the report.
Boston Children’s Hospital will also reimburse IDI for half the “salary, benefits and start-up expenses associated with up to three new faculty recruits for up to three years,” according to the report.
The deal — which closed yesterday — builds on an affiliation the hospital and institute have held for nearly four years centered around the research and development of immunology therapies, according to the report.
More Articles on Hospitals for Children:
American Academy of Pediatrics Revises Definitions of Newborn Care Levels
Texas Children’s Hospital Names Cancer Center Clinic After Two Donors
Arkansas Children’s, University of Arkansas for Medical Sciences Open New Center
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
